CF PharmTech, Inc. disclosed that it repurchased 71,800 H shares on 02 October 2026 via on-market transactions on the Hong Kong Stock Exchange. The buyback was executed within a price range of HKD 6.885–7.255 per share, translating into an aggregate outlay of HKD 0.50 million. The volume-weighted average repurchase price stood at HKD 6.96 per share.

Following the transaction, the company’s outstanding share count (excluding treasury shares) fell by 0.0223 % to 322.16 million, while treasury shares increased to 1.81 million. Total issued shares remained unchanged at 323.97 million, as the repurchased stock is being held in treasury rather than cancelled.

The purchase forms part of the repurchase mandate approved on 26 June 2026, which authorises CF PharmTech to buy back up to 30.08 million shares. Including the latest transaction, the company has acquired 409,600 shares under this authority—equivalent to 0.14 % of the issued share base at the time the mandate was granted.

In accordance with Hong Kong listing rules, CF PharmTech is subject to a moratorium on issuing new shares or disposing of treasury shares until 01 November 2026.